Changes in anxiety and depression symptoms associated to the outcome of MOH: A post-hoc analysis of the Comoestas Project

the Comoestas Consortium

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aims: To evaluate the impact of treatment success on depression and anxiety symptoms in medication-overuse headache (MOH) and whether depression and anxiety can be predictors of treatment outcome. Methods: All consecutive patients entering the detoxification program were analysed in a prospective, non-randomised fashion over a six-month period. Depression and anxiety were assessed using the Hospital Anxiety and Depression Scale. Results: A total of 663 MOH patients were evaluated, and 492 completed the entire protocol. Of these, 287 ceased overuse and reverted to an episodic pattern (responders) and 23 relapsed into overuse. At the final evaluation, the number of patients with depressive symptoms was reduced by 63.2% among responders (p < 0.001) and did not change in relapsers (p = 0.13). Anxious symptomatology was reduced by 43.1% in responders (ps < 0.001) and did not change in relapsers (p = 0.69). At the multivariate analysis, intake of a prophylactic drug and absence of symptoms of depression at six months emerged as prognostic factors for being a responder (OR 2.406; p = 0.002 and OR 1.989; p = 0.019 respectively), while lack of antidepressant drugs and presence of symptoms of depression at six months were prognostic factors for relapse into overuse (OR 3.745; p = 0.004 and OR 3.439; p = 0.031 respectively). Conclusions: Symptomatology referred to affective state and anxiety can be significantly reduced by the treatment of MOH. Baseline levels of depression and anxiety do not generally predict the outcome at six months. Their persistence may represent a trait of patients with a negative outcome, rather than the consequence of a treatment failure.

Original languageEnglish
Pages (from-to)646-654
Number of pages9
JournalCephalalgia
Volume38
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Secondary Headache Disorders
Anxiety
Depression
Treatment Failure
Antidepressive Agents
Multivariate Analysis

Keywords

  • detoxification failure
  • follow-up
  • Medication-overuse headache
  • psychological factors

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Changes in anxiety and depression symptoms associated to the outcome of MOH : A post-hoc analysis of the Comoestas Project. / the Comoestas Consortium.

In: Cephalalgia, Vol. 38, No. 4, 01.04.2018, p. 646-654.

Research output: Contribution to journalArticle

@article{6015ac03b93b45d997f65e1f7ce98b05,
title = "Changes in anxiety and depression symptoms associated to the outcome of MOH: A post-hoc analysis of the Comoestas Project",
abstract = "Aims: To evaluate the impact of treatment success on depression and anxiety symptoms in medication-overuse headache (MOH) and whether depression and anxiety can be predictors of treatment outcome. Methods: All consecutive patients entering the detoxification program were analysed in a prospective, non-randomised fashion over a six-month period. Depression and anxiety were assessed using the Hospital Anxiety and Depression Scale. Results: A total of 663 MOH patients were evaluated, and 492 completed the entire protocol. Of these, 287 ceased overuse and reverted to an episodic pattern (responders) and 23 relapsed into overuse. At the final evaluation, the number of patients with depressive symptoms was reduced by 63.2{\%} among responders (p < 0.001) and did not change in relapsers (p = 0.13). Anxious symptomatology was reduced by 43.1{\%} in responders (ps < 0.001) and did not change in relapsers (p = 0.69). At the multivariate analysis, intake of a prophylactic drug and absence of symptoms of depression at six months emerged as prognostic factors for being a responder (OR 2.406; p = 0.002 and OR 1.989; p = 0.019 respectively), while lack of antidepressant drugs and presence of symptoms of depression at six months were prognostic factors for relapse into overuse (OR 3.745; p = 0.004 and OR 3.439; p = 0.031 respectively). Conclusions: Symptomatology referred to affective state and anxiety can be significantly reduced by the treatment of MOH. Baseline levels of depression and anxiety do not generally predict the outcome at six months. Their persistence may represent a trait of patients with a negative outcome, rather than the consequence of a treatment failure.",
keywords = "detoxification failure, follow-up, Medication-overuse headache, psychological factors",
author = "{the Comoestas Consortium} and Sara Bottiroli and Marta Allena and Grazia Sances and {De Icco}, Roberto and Micol Avenali and Ricardo Fadic and Zaza Katsarava and Lainez, {Miguel J.A.} and Goicochea, {Maria Teresa} and Jensen, {Rigmor H{\o}jland} and Giuseppe Nappi and Cristina Tassorelli",
year = "2018",
month = "4",
day = "1",
doi = "10.1177/0333102417704415",
language = "English",
volume = "38",
pages = "646--654",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Changes in anxiety and depression symptoms associated to the outcome of MOH

T2 - A post-hoc analysis of the Comoestas Project

AU - the Comoestas Consortium

AU - Bottiroli, Sara

AU - Allena, Marta

AU - Sances, Grazia

AU - De Icco, Roberto

AU - Avenali, Micol

AU - Fadic, Ricardo

AU - Katsarava, Zaza

AU - Lainez, Miguel J.A.

AU - Goicochea, Maria Teresa

AU - Jensen, Rigmor Højland

AU - Nappi, Giuseppe

AU - Tassorelli, Cristina

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Aims: To evaluate the impact of treatment success on depression and anxiety symptoms in medication-overuse headache (MOH) and whether depression and anxiety can be predictors of treatment outcome. Methods: All consecutive patients entering the detoxification program were analysed in a prospective, non-randomised fashion over a six-month period. Depression and anxiety were assessed using the Hospital Anxiety and Depression Scale. Results: A total of 663 MOH patients were evaluated, and 492 completed the entire protocol. Of these, 287 ceased overuse and reverted to an episodic pattern (responders) and 23 relapsed into overuse. At the final evaluation, the number of patients with depressive symptoms was reduced by 63.2% among responders (p < 0.001) and did not change in relapsers (p = 0.13). Anxious symptomatology was reduced by 43.1% in responders (ps < 0.001) and did not change in relapsers (p = 0.69). At the multivariate analysis, intake of a prophylactic drug and absence of symptoms of depression at six months emerged as prognostic factors for being a responder (OR 2.406; p = 0.002 and OR 1.989; p = 0.019 respectively), while lack of antidepressant drugs and presence of symptoms of depression at six months were prognostic factors for relapse into overuse (OR 3.745; p = 0.004 and OR 3.439; p = 0.031 respectively). Conclusions: Symptomatology referred to affective state and anxiety can be significantly reduced by the treatment of MOH. Baseline levels of depression and anxiety do not generally predict the outcome at six months. Their persistence may represent a trait of patients with a negative outcome, rather than the consequence of a treatment failure.

AB - Aims: To evaluate the impact of treatment success on depression and anxiety symptoms in medication-overuse headache (MOH) and whether depression and anxiety can be predictors of treatment outcome. Methods: All consecutive patients entering the detoxification program were analysed in a prospective, non-randomised fashion over a six-month period. Depression and anxiety were assessed using the Hospital Anxiety and Depression Scale. Results: A total of 663 MOH patients were evaluated, and 492 completed the entire protocol. Of these, 287 ceased overuse and reverted to an episodic pattern (responders) and 23 relapsed into overuse. At the final evaluation, the number of patients with depressive symptoms was reduced by 63.2% among responders (p < 0.001) and did not change in relapsers (p = 0.13). Anxious symptomatology was reduced by 43.1% in responders (ps < 0.001) and did not change in relapsers (p = 0.69). At the multivariate analysis, intake of a prophylactic drug and absence of symptoms of depression at six months emerged as prognostic factors for being a responder (OR 2.406; p = 0.002 and OR 1.989; p = 0.019 respectively), while lack of antidepressant drugs and presence of symptoms of depression at six months were prognostic factors for relapse into overuse (OR 3.745; p = 0.004 and OR 3.439; p = 0.031 respectively). Conclusions: Symptomatology referred to affective state and anxiety can be significantly reduced by the treatment of MOH. Baseline levels of depression and anxiety do not generally predict the outcome at six months. Their persistence may represent a trait of patients with a negative outcome, rather than the consequence of a treatment failure.

KW - detoxification failure

KW - follow-up

KW - Medication-overuse headache

KW - psychological factors

UR - http://www.scopus.com/inward/record.url?scp=85044747317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044747317&partnerID=8YFLogxK

U2 - 10.1177/0333102417704415

DO - 10.1177/0333102417704415

M3 - Article

AN - SCOPUS:85044747317

VL - 38

SP - 646

EP - 654

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 4

ER -